Australia’s CSL tumbles after heart attack drug trial falls through Shares of Australian pharmaceutical giant CSL Ltd (ASX:CSL) tumbled on Monday after it said that a phase 3 trial for a drug to treat second heart attacks had failed to meet its primary endpoint in efficacy.

CSL shares fell 4.5% to A$291.35, and were among the biggest weights on the broader ASX 200 index, which fell  0.1%. Shares of the pharmaceutical firm were also set for their worst day in four months.

CSL said in an announcement that a phase 3 trial for CSL112 did not meet its primary endpoint of reducing “major adverse cardiovascular events” in the 90 day, high-risk period after an initial heart attack. 

The firm said that following the study, there were no plans to pursue a regulatory filing for the drug in the near-term. CSL also said that the CSL112 trial was not expected to have “any material financial impact.” 

The study had enrolled over 18,200 patients and covered 49 countries, with CSL calling the study "the most ambitious study" in the company's history.

“Substantial work remains to fully analyse and understand the complete data and then to determine any development path ahead for this asset,” Bill Mezzanotte, Executive Vice President, Head of R&D at CSL said in a statement. 

Mezanotte added that the firm would still leverage some aspects of the AEGIS-II study for finding medical needs in other cardiovascular and metabolic conditions.

The announcement came just a day ahead of CSL’s earnings for the six months to December 31. CSL said it will provide more details on the phase 3 study during an earnings briefing on Tuesday. 

Begin trading today! Create an account by completing our form

Privacy Notice

At One Financial Markets we are committed to safeguarding your privacy.

Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.

Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.

Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.

By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76.3% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Back to top

Office network

One Financial Markets is the trading name of Axi Financial Services (UK) Ltd, a company registered in England with company number 6050593. Axi Financial Services (UK) Ltd is authorised and regulated by the Financial Conduct Authority in the UK (under firm reference number 466201) and the Financial Sector Conduct Authority in South Africa (with FSP number 45784).

The information on this site is not directed at residents of the United States, Belgium, Poland or any particular country outside the UK and is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation. is owned and operated by Axi Financial Services (UK) Ltd.

Award winning broker
We have been presented with a number of awards that recognise the quality of our service and dedication to our clients :

Best FSA Regulated Broker
Saudi Money Expo

Best Education Product
Saudi Money Expo

Best Broker - Online Trading
IAIR Awards

Best Institutional Broker
Saudi Money Expo

Best FX Services Broker
CN Forex

Top International
FX Broker 2015

Saudi Money Expo

Broker of the Year
Online Trading – Middle East

IAIR Awards

Best Forex
Customer Service 2018

JFEX Awards

We accept the following payment methods: